The role of soluble and cell-surface expressed 4-1BB ligand in patients with malignant hemopoietic disorders

References

• Locksley R M, Killeen N, Leonardo M J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487–501
   PubMed Web of Science ®Google Scholar
• Pan P-Y, Gu P, Li Qingsheng, Xu D, Weber K, Chen S-H. Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. J Immunol 2004; 172: 4779–4789
   PubMed Web of Science ®Google Scholar
• Laderach D, Wesa A, Galy A. 4-1BB-ligand is regulated on human dendritic cells and induces the production of IL-12. Cell Immunol 2003; 226: 37–44
   PubMed Web of Science ®Google Scholar
• Watts T H. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005; 23: 23–68
   PubMed Web of Science ®Google Scholar
• Goodwin R G, Din W S, Davis-Smith T, Anderson D M, Gimpel S D, Sato T A, et al. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur J Immunol 1993; 23: 2631
   PubMed Web of Science ®Google Scholar
• Hurtado J C, Kim S H, Pollok K E, Lee Z H, Kwon B S. Potential role of 4-1BB in T cell activation: comparison with the costimulatory molecule CD28. J Immunol 1995; 155: 3360
   PubMed Web of Science ®Google Scholar
• DeBenedette M A, Shahinian A, Mak T W, Watts T H. Costimulation of CD28− T lymphocytes by 4-1BB ligand. J Immunol 1997; 158: 551
   PubMed Web of Science ®Google Scholar
• Chu N R, DeBenedette M A, Stiernholm B JN, Barber B H, Watts T H. Role of IL-12 and 4-1BB ligand in cytokine production by CD28+ and CD28-T cells. J Immunol 1997; 158: 3081
   PubMed Web of Science ®Google Scholar
• Melero W, Shuford W, Newby S A, Aruffo A, Ledbetter J A, Hellstrom K E, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997; 3: 682
   PubMed Web of Science ®Google Scholar
• Shuford W W, Klussman K, Tritchler D D, Loo D T, Chalupny J, Siadak A W, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997; 186: 47
   PubMed Web of Science ®Google Scholar
• Takahashi C, Mittler R S, Vella A T. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 1999; 162: 5037
   PubMed Web of Science ®Google Scholar
• Salih H R, Kosowski S G, Haluska V F, Starling G C, Loo D T, Lee F, et al. Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells. J Immunol 2000; 165: 2903–2910
   PubMed Web of Science ®Google Scholar
• Michel J, Pauly S, Langstein P, Krammer P H, Schwarz H. CD137 induced apoptosis is independent of CD95. Immunology 1999; 98: 42
   PubMed Web of Science ®Google Scholar
• Palma C, Binaschi M, Bigioni M, Maggi C A, Goso C. CD137 and CD137 ligand constitutively expressed on human T and B leucemia cells signal proliferation and survival. Int J Cancer 2004; 108: 390–398
   PubMed Web of Science ®Google Scholar
• Jung H W, Choi J I, Kwon B S. Serum concentrations of solubile 4-1BB ligand correlated with the disease severity in rheumatoid arthritis. Exp Mol Med 2004; 29;36: 13–22
   Web of Science ®Google Scholar
• Salih H R, Schmetzer H M, Burke C, Starling G C, Dunn R, Pelka-Fleischer R, et al. Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies. J Immunol 2001; 167: 4059–4066
   PubMed Web of Science ®Google Scholar
• Molica S, Vitelli G, Levato D, Crispino G, Dell'Olio M, Dattilo A, et al. CD27 in B-cell chronic lymphocytic leukemia. Cellular expression, serum release and correlation with other soluble molecules belonging to nerve growth factor receptors (NGFr) superfamily. Haematologica 1998; 83: 398–402
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, et al. Proposals for the classification of the acute leukemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451–458
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199
   PubMed Web of Science ®Google Scholar
• Salih H R, Nuessler V, Claudio D, Starling G C, Peter A. Serum levels of CD137 ligand and CD178 are prognostic factors for progression of myelodysplastic syndrome. Leuk Lymphoma 2004; 45: 301–308
   PubMed Web of Science ®Google Scholar
• Schmetzer H M, Kremser A, Loibl J, Kroell T, Kolb H J. Quantification of ex vivo generated dendritic cells (DC) and leukemia-derived DC contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell-activation-procedures ex vivo or in vivo. Leukemia 2007; 21: 1338–1341
   PubMed Web of Science ®Google Scholar
• Lee A W, Truong T, Bickham K, Fonteneau J-F, Larsson M, Da Silva I, et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 2002; 20: A8–A22
   PubMed Web of Science ®Google Scholar
• Westers T M, Stam A GM, Scheper R J, Regelink J C, Nieuwint A W, Schuurhuis G J, Loosdrecht A A, et al. Rapid generation of antigen-presenting cells from leukemic blasts in acute myeloid leukemia. Cancer Immunol Immunother 2003; 52: 17–27
   PubMed Web of Science ®Google Scholar
• Houtenbos I, Westers T M, Stam A G, de Gruijl T D, Scheper R J, Ossenkoppele G J, Loosdrecht A A, et al. Serum-free generation of antigen presenting cells from acute myeloid leukemic blasts for active specific immunisation. Cancer Immunol Immunother 2003; 52: 455–462
   PubMed Web of Science ®Google Scholar
• Schuler G, Schuler-Thurner B, Steinman R M. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003; 15: 138–147
   PubMed Web of Science ®Google Scholar
• Kufner S, Pelka Fleischer R, Kroell T, Schmid C, Zitzelsberger H, Salih H, et al. Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes. Cancer Immunol Immunother 2005; 54: 953–970
   PubMed Web of Science ®Google Scholar
• Kremser A, Loibl J, Scholl N, Schmid C, Kufner S, Schweiger C, et al. Dendritic cells generated from leukemic blasts an evaluation of different methods. submitted 2009
   Google Scholar
• Loibl J, Kremser A, Schmid C, Zitzelsberger H, Buhmann R, Kroell T, et al. Surface marker expression profiles have to be evaluated before and after the generation of dendritic cells (DC) from blasts in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) to characterize and quantify DC in experimental settings. submitted 2009
   Google Scholar
• Sato M, Takayama T, Tanaka H, Konishi J, Suzuki T, Kaiga T, et al. Generation of mature dendritic cells fully capable of T helper type 1 polarization using OK-432 combined with prostaglandin E(2). Cancer Sci 2003; 94: 1091–1098
   PubMed Web of Science ®Google Scholar
• Hentschel N, Krusch M, Kiener P A, Kolb H J, Salih H R, Schmetzer H M. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma. Eur J Haematol 2006; 77: 91–101
   PubMed Web of Science ®Google Scholar
• Armitage R J, Fanslow W C, Strockbine L, Sato T A, Clifford K N, Macduff B M, et al. Molecular and biological characterization of a murine ligand for CD40. Nature 1992; 357: 80
   PubMed Web of Science ®Google Scholar
• Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169
   PubMed Web of Science ®Google Scholar
• Alderson M R, Smith C A, Tough T W, Davis-Smith T, Armitage R J, Falk B, et al. Molecular and biological characterization of human 4-1BB and its ligand. Eur J Immunol 1994; 24: 2219
   PubMed Web of Science ®Google Scholar
• Saoulli K, Lee S Y, Cannons J L, Yeh W C, Santana A, Goldstein M D, et al. CD28-independent, TRAF2-dependent costimualtion of resting T cells by -1BB ligand. J Exp Med 1998; 187: 1849
   PubMed Web of Science ®Google Scholar
• Walker P R, Saas P, Dietrich P-Y. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 1997; 158: 4521
   PubMed Web of Science ®Google Scholar
• Lee P-K, Chang C-J, Lin C-M. Lipopolysaccharide preferentially induces 4-1BB ligand expression on human monocyte-derived dendritic cells. Immunol Lett 2003; 90: 215–221
   PubMed Web of Science ®Google Scholar
• Salih H R, Starling G C, Knauff M, Davis P M, Pitts W J, Aruffo A, et al. Retinoic acid and vitamin E modulate expression and release of CD178 in carcinoma cells: consequences for instructions of apoptosis in CD95 sensitive cells. Exp Cell Res 2001; 270: 248–258
   PubMed Web of Science ®Google Scholar
• Lickliter J D, Kratzke A, Nguyen P L, Niehans G A, Miller J S. Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis. Exp Hematol 1999; 27: 1519–1527
   PubMed Web of Science ®Google Scholar
• Lee S W, Park Y, So T, Kwon B S, Cheroutre H, Mittler R S, et al. Identification of regulatory functions for 4-1BBL and 4-1BBL in myelopoiesis and the development of dendritic cells. Nat Immunol 2008; 9: 917–926
   PubMed Web of Science ®Google Scholar